Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer

NCT00042978 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

NIH

Sponsor class

Conditions

Extensive Stage Small Cell Lung Cancer
Recurrent Small Cell Lung Cancer

Interventions

BIOLOGICAL: oblimersen sodium
DRUG: carboplatin
DRUG: etoposide

Sponsor

National Cancer Institute (NCI)